Home › Chronic Myelomonocytic Leukemia › Washington › Seattle
Chronic Myelomonocytic Leukemia clinical trials in Seattle, WA
11 studies for Chronic Myelomonocytic Leukemia are looking for participants at sites in and around Seattle (within about 30 miles). Open a study to see who can join and how to contact the study team.
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
RecruitingPhase 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
RecruitingPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
RecruitingPhase 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
RecruitingPhase 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RecruitingPhase 2Healthy volunteers welcome
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
RecruitingPhase 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
RecruitingPhase 1/2Healthy volunteers welcome
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RecruitingPhase 2/3
- Seattle Cancer Care Alliance, Seattle
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
RecruitingPhase 2
- Fred Hutchinson Cancer Center, Seattle
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
RecruitingPhase 1
- Fred Hutchinson Cancer Center, Seattle
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
RecruitingPhase 1
- University of Washington/Fred Hutchinson Cancer Center, Seattle
Chronic Myelomonocytic Leukemia trials in other cities
- Houston, TX17 studies
- Boston, MA8 studies
- Rochester, MN7 studies
- Mountain View, CA6 studies
- Baldwin Park, CA6 studies
- New York City, NY6 studies
- Durham, NC5 studies
- Tampa, FL4 studies
- Miami, FL4 studies
- Atlanta, GA4 studies
- Birmingham, AL4 studies
- Columbus, OH4 studies
Other studies in Seattle
- Non-Small Cell Lung Cancer53 studies
- Cancer (all types)50 studies
- Prostate Cancer44 studies
- Breast Cancer40 studies
- Acute Myeloid Leukemia40 studies
- Metastatic Cancer39 studies
- Colorectal Cancer34 studies
- Lung Cancer33 studies
- Ovarian Cancer31 studies
- Multiple Myeloma22 studies
- Pancreatic Cancer22 studies
- Myelodysplastic Syndromes21 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.